Philipp Stephan, Sosna Justyna, Adam Dieter
Institut für Immunologie, Christian-Albrechts-Universität, Michaelisstraße 5, 24105, Kiel, Germany.
Cell Mol Life Sci. 2016 Jun;73(11-12):2183-93. doi: 10.1007/s00018-016-2193-2. Epub 2016 Apr 5.
Regulated cell death is one major factor to ensure homoeostasis in multicellular organisms. For decades, apoptosis was considered as the sole form of regulated cell death, whereas necrosis was believed to be accidental and unregulated. Due to this view, research on necrosis was somewhat neglected, especially in the field of anti-cancer treatment. However, new interest in necrosis has been sparked by the recent discovery of different forms of necrosis that show indeed regulated pathways. More and more studies now address the molecular pathways of regulated necrosis and its connections within the cellular signaling networks. Necroptosis, a subform of regulated necrosis, has so far hardly been focused on with regard to a future treatment of cancer patients and may emerge as a novel and effective approach to eliminate tumor cells. However, and similar to apoptosis, tumor cells can develop resistances against necroptosis to ensure their own survival. In this context, new molecules that enhance necroptosis are currently being identified to overcome such resistances. This review discusses cancer and necroptosis as friends or foes, i.e. the options to exploit necroptosis in anti-cancer therapies ("foes"), but also potential limitations that may block or actually cause necroptosis to act in a protumoral manner ("friends"). The balance between these two possible roles will determine whether necroptosis can indeed be used as a promising tool for early diagnosis of tumors, prevention of metastasis and anti-cancer treatment.
调节性细胞死亡是确保多细胞生物体内稳态的一个主要因素。几十年来,细胞凋亡被认为是调节性细胞死亡的唯一形式,而坏死则被认为是意外的且不受调节的。由于这种观点,对坏死的研究在一定程度上被忽视了,尤其是在抗癌治疗领域。然而,最近发现了不同形式的坏死,其显示出确实存在调节途径,这引发了对坏死的新兴趣。现在越来越多的研究关注调节性坏死的分子途径及其在细胞信号网络中的联系。坏死性凋亡是调节性坏死的一种亚型,就未来癌症患者的治疗而言,目前几乎没有受到关注,它可能会成为一种消除肿瘤细胞的新颖且有效的方法。然而,与细胞凋亡类似,肿瘤细胞可以对坏死性凋亡产生抗性以确保自身存活。在这种情况下,目前正在鉴定增强坏死性凋亡的新分子以克服这种抗性。这篇综述讨论了癌症与坏死性凋亡是敌是友,即探讨在抗癌治疗中利用坏死性凋亡的可能性(“敌”),同时也讨论了可能阻碍或实际上导致坏死性凋亡以促肿瘤方式发挥作用的潜在限制(“友”)。这两种可能作用之间的平衡将决定坏死性凋亡是否真的可以用作肿瘤早期诊断、预防转移和抗癌治疗的有前景的工具。